9c46145e_nter___Yale_School_of_Medicine__Conditions
[Study Title] A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma. [Conditions] 
Melanoma, skin
M e l a n o m a , s k i n
S o f t T i s s u e
Mario Sznol, MD > Yale Cancer Center | Yale School of Medicine
Conditions